NNVC Keeping it real board for pro and con discussions Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC Keeping it real board for pro and con discussions

NNVC 1.680

-8.7%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: HardToFind who wrote (325)	4/20/2020 10:15:21 AM
From: Savant	of 326

Boston, MA -- ( ReleaseWire) -- 04/09/2020 --BIOXYTRAN, INC., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the brain, heart, lungs, and other vital organs is announcing the launch of a new presentation detailing the expected mechanism of action between BXT-10 and COVID-19 in order to reduce the viral load. Presentation Link: uploads-ssl.webflow.com Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis. The journal article titled Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis demonstrates how viral pathogenesis is dependent upon galectin-1 in preclinical studies. The article demonstrated the direct binding of galectin-1 to the influenza virus. Yang et. al. indicated that "intranasal treatment of galectin-1 could enhance survival of mice against lethal challenge with influenza virus by reducing viral load, inflammation, and apoptosis in the lung." This galectin-1 treatment resulted in a survival benefit of the mice and indicated theoretical mechanisms of action (MOA) in humans. The journal article titled Crystal Structure of Bovine Coronavirus Spike Protein Lectin Domain explored the evolution of the coronavirus N-terminal domains (NTDs) which are commonly referred to as coronavirus protein spikes. Guiguing Peng et. al. concluded that "Bovine coronavirus NTD shares structural folds and sugar-binding sites with human galectins and has subtle yet functionally important differences from protein-binding NTD of mouse coronavirus." This study confirmed the linkage between the mouse coronavirus and humans. There is much evidence to show that the coronavirus can jump between species. Since this receptor is similar on both species there is a consensus among the Scientific advisory board that this will translate to efficacy in humans. The 2015 article titled, Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies demonstrated the similarities between influenza and SARS. Dr Fang Li said "the following evolutionary scenario has been proposed for coronavirus S1-NTDs. Through gene capture, ancestral coronaviruses might have acquired a host galectin, which would become the S1-NTD of their spikes. Consequently, coronaviruses would recognize sugar receptors for cell entry." Analysis of the crystalline structures showed the linkage between influenza and SARS. COVID-19 is also known as SARS-CoV2 which is indicative that it is a subspecies of SARS. The SARS virus has a "galectin fold" which in theory represents a binding spot on the virus for Bioxytran's galectin-1 inhibitor. "The journal articles provide a strong foundation that galectin-1 is implicated in COVID-19," said CEO David Platt of Bioxytran Inc. and co-author of Galectin. "It is clear in preclinical studies that galectin-1 was implicated in pathogenesis of the virus in mice. Further study showed that the mice share the same N-terminal domain as humans. There are also many similarities between SARS and COVID-19 because they share the similar N-terminal domain. Based on these linkages the scientific team at Bioxytran formed its thesis that a galectin-1 inhibitor could bind to the coronavirus spikes and reduce viral load. With the proper funding the company could be in human trials shortly." releasewire.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext